Incyte Corporation (INCY)

Incyte Corporation (INCY $102.62)
- $102.62 P/E (TTM): 18.16X Cap: $20.14B
- View INCY Profile
- View Questions on INCY

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

Intuitive Surgical Inc. (ISRG $527.44)
- $527.44 P/E (TTM): 70.67X Cap: $186.97B
- View ISRG Profile
- View Questions on ISRG
Vertex Pharmaceuticals Incorporated (VRTX $442.08)
- $442.08 P/E (TTM): 30.86X Cap: $111.98B
- View VRTX Profile
- View Questions on VRTX
AbbVie Inc. (ABBV $214.04)
- $214.04 P/E (TTM): 163.63X Cap: $378.29B
- View ABBV Profile
- View Questions on ABBV
Johnson & Johnson (JNJ $218.21)
- $218.21 P/E (TTM): 21.11X Cap: $526.81B
- View JNJ Profile
- View Questions on JNJ
Eli Lilly and Company (LLY $1,041.29)
- $1,041.29 P/E (TTM): 50.8X Cap: $981.68B
- View LLY Profile
- View Questions on LLY
Merck & Company Inc. (MRK $109.45)
- $109.45 P/E (TTM): 14.39X Cap: $270.11B
- View MRK Profile
- View Questions on MRK
iShares Biotechnology ETF (IBB $170.72)
- $170.72 P/E (TTM): 21.3X Cap: $8.53B
- View IBB Profile
- View Questions on IBB
IDEXX Laboratories Inc. (IDXX $686.02)
- $686.02 P/E (TTM): 56.73X Cap: $54.77B
- View IDXX Profile
- View Questions on IDXX
Halozyme Therapeutics Inc. (HALO $70.43)
- $70.43 P/E (TTM): 16.3X Cap: $8.28B
- View HALO Profile
- View Questions on HALO
Incyte Corporation (INCY $102.62)
- $102.62 P/E (TTM): 18.16X Cap: $20.14B
- View INCY Profile
- View Questions on INCY
Catalyst Pharmaceuticals Inc. (CPRX $23.38)
- $23.38 P/E (TTM): 13.2X Cap: $2.79B
- View CPRX Profile
- View Questions on CPRX
Gilead Sciences CDR (CAD Hedged) (GILD $25.53)
- $25.53 P/E (TTM): 328.71X Cap: $210.04B
- View GILD Profile
- View Questions on GILD

Q: We have accumulated 11 healthcare stocks and 1 ETF, While LLY and ISRG are at half positions the rest are at initial 25% positions. Please advise [help!] us get to a more concentrated portfolio with a 3+ year horizon for reasonable opportunities in healthcare

Read Answer Asked by sam on January 13, 2026

NV5 Global Inc. (NVEE $22.56)
- $22.56 P/E (TTM): 49.04X Cap: $1.48B
- View NVEE Profile
- View Questions on NVEE
Axon Enterprise Inc. (AXON $620.52)
- $620.52 P/E (TTM): 201.66X Cap: $49.25B
- View AXON Profile
- View Questions on AXON
Applied Industrial Technologies Inc. (AIT $277.44)
- $277.44 P/E (TTM): 27.07X Cap: $10.46B
- View AIT Profile
- View Questions on AIT
Incyte Corporation (INCY $102.62)
- $102.62 P/E (TTM): 18.16X Cap: $20.14B
- View INCY Profile
- View Questions on INCY
Extreme Networks Inc. (EXTR $15.02)
- $15.02 P/E (TTM): 266.0X Cap: $2B
- View EXTR Profile
- View Questions on EXTR
InMode Ltd. (INMD $13.82)
- $13.82 Cap: $969M
- View INMD Profile
- View Questions on INMD
Taboola.com Ltd. (TBLA $4.09)
- $4.09 P/E (TTM): 52.25X Cap: $1.22B
- View TBLA Profile
- View Questions on TBLA
Lantheus Holdings Inc. (LNTH $65.88)
- $65.88 P/E (TTM): 27.11X Cap: $4.26B
- View LNTH Profile
- View Questions on LNTH
Catalyst Pharmaceuticals Inc. (CPRX $23.38)
- $23.38 P/E (TTM): 13.2X Cap: $2.79B
- View CPRX Profile
- View Questions on CPRX

Q: In one of your recent answers you said, "the small mid cap tech and industry and pharma sectors in the US are the places to be". Could you please give some specific names that would fall in those categories? Thank you

Read Answer Asked by Neil on December 05, 2022

Incyte Corporation (INCY $102.62)
- $102.62 P/E (TTM): 18.16X Cap: $20.14B
- View INCY Profile
- View Questions on INCY

Q: What do you think of Incyte's product line, long term upside/or downside potential is? What are the pros and cons of this stock, concerning the market they are in and where would they rank against their competitors, the financial ratios, insider buying/selling(which alerted me to this stock) and your opinion on the management ? Would you consider it a buy, hold or sell at this time? Thanks

Read Answer Asked by James on March 04, 2022